ARHGEF1 and hypertensive disorder: These insights not only elucidate cardiovascular disease mechanisms but also highlight potential GEF‐targeted therapies (e.g., against VAV3, ARHGEF1, TIAM1, or PDZ‐RhoGEF) for hypertension, atherosclerosis, and myocardial regeneration.